1
Sept 30 (Reuters) – The U.S. Food and Drug Administration has approved Novartis' oral treatment for patients with type of chronic inflammatory skin disease, the company said on Tuesday. (Reporting by Siddhi Mahatole in Bengaluru; Editing by Sahal Muhammed)
(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)
